Evolus, Inc. (EOLS) News

Evolus, Inc. (EOLS): $6.98

-0.35 (-4.77%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter EOLS News Items

EOLS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

EOLS News Highlights

  • EOLS's 30 day story count now stands at 3.
  • Over the past 2 days, the trend for EOLS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.

Latest EOLS News From Around the Web

Below are the latest news stories about EVOLUS INC that investors may wish to consider to help them evaluate EOLS as an investment opportunity.

Evolus Third Quarter 2022 Earnings: Revenues Disappoint

Evolus ( NASDAQ:EOLS ) Third Quarter 2022 Results Key Financial Results Revenue: US$33.9m (up 27% from 3Q 2021). Net...

Yahoo | November 10, 2022

Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -18.52% and 8.22%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 8, 2022

Evolus Reports Third Quarter 2022 Results and Provides Business Update

NEWPORT BEACH, Calif., November 08, 2022--Evolus reports financial results for the third quarter ended September 30, 2022 and provides a business update.

Yahoo | November 8, 2022

Evolus to Participate in November Conferences

NEWPORT BEACH, Calif., November 02, 2022--Evolus announces that members of its management team will be participating in two investment conferences in November.

Yahoo | November 2, 2022

Evolus to Report Third Quarter 2022 Results and Provide Business Update

NEWPORT BEACH, Calif., October 25, 2022--Evolus announces that it will report its third quarter 2022 financial results and provide a business update on Tuesday, November 8, 2022.

Yahoo | October 25, 2022

Evolus Broadens Its International Presence with Nuceiva® Launch in Great Britain

NEWPORT BEACH, Calif., October 04, 2022--Evolus, Inc., launched commercial operations in Great Britain and shipped the first customer orders for Nuceiva®▼(botulinum toxin type A) last month.

Yahoo | October 4, 2022

Evolus Concludes Certain Royalty Payments; Financial Profile Improves Significantly Starting in the Fourth Quarter of 2022

NEWPORT BEACH, Calif., September 21, 2022--Evolus celebrates the conclusion of certain royalty payments that resulted from the 2021 settlement of litigation claims.

Yahoo | September 21, 2022

13 Stocks to Sell Now According to Billionaire Larry Robbins

In this article, we will discuss the 13 stocks to sell now according to billionaire Larry Robbins. If you want to skip the detailed analysis of Robbins’ investment philosophy, go directly to 5 Stocks to Sell Now According to Billionaire Larry Robbins. American investor and philanthropist Larry Robbins was born in 1969. Glenview Capital Management, […]

Yahoo | September 20, 2022

This Options Play Could Turn That Frown Upside Down

Evolus, Inc. is small-cap company rapidly taking market share in the growing "aesthetic neurotoxin" space -- a.k.a. Using the April $10 call strikes, fashion a covered call order with a net debit in the $7.60 to $7.80 a share range (net stock price - option premium).

Yahoo | September 18, 2022

There's a New Way to Get Rid of Wrinkles

For a very long time, Botox was synonymous with the facial injections industry — the drug made by pharma company Allergan was approved for cosmetic use in 2002 and has since become widely used as an anti-wrinkle cosmetics treatment. Botox's dominance of the anti-wrinkle market slowly started to shift with the emergence of new products on the scene. In 2019, the Federal Drug Administration (FDA) approved the Jeuveau injectable serum made by beauty company Evolus .

Yahoo | September 9, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4775 seconds.